<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35064378</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>16</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1573-2576</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>45</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Inflammation</Title>
          <ISOAbbreviation>Inflammation</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Expressions of Interleukin-27 in Oral Lichen Planus, Oral Leukoplakia, and Oral Squamous Cell Carcinoma.</ArticleTitle>
        <Pagination>
          <StartPage>1023</StartPage>
          <EndPage>1038</EndPage>
          <MedlinePgn>1023-1038</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10753-021-01599-5</ELocationID>
        <Abstract>
          <AbstractText>The present study aimed to detect the expression of interleukin-27 (IL-27) in tissues of oral lichen planus (OLP), oral leukoplakia (OLK), and oral squamous cell carcinoma (OSCC) and to investigate the possible role of IL-27 in the above diseases and whether it was involved in the onset and development of the tumor. Paraffin tissues from patients with OLP, OLK, and OSCC were collected, and the expression of IL-27 in the above tissues was detected by immunohistochemical (IHC) staining. Parameters were obtained from the images by the Image-Pro Plus (IPP) image analysis software, and statistical analysis was performed using relevant data. The expressions of IL-27 were significantly higher in specimens with OLP, OLK, and OSCC than those in the healthy group. In OLP, the expression of IL-27 was positively correlated with the degree of lymphocyte infiltration and basal cell liquefaction while independent of the clinical type. In OLK, the expression of IL-27 was positively correlated with abnormal epithelial cell proliferation. In OSCC, the expression of IL-27 was correlated with the degree of squamous cell differentiation and was independent of gender, TNM stage, and lymphatic metastasis. The expressions of IL-27 were significantly higher in tissues with severe OLP and OLK than that in the control group, while similar to that in highly differentiated OSCC. The expressions of IL-27 were significantly elevated in tissues with OLP, OLK, and OSCC, suggesting that IL-27 might be involved in the development of these diseases and play a role in the carcinogenesis of oral precancerous lesions.</AbstractText>
          <CopyrightInformation>© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Wang</LastName>
            <ForeName>Qing-Mei</ForeName>
            <Initials>QM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Stomatology, Union Hospital, Fujian Medical University, Fuzhou, 350001, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Huang</LastName>
            <ForeName>Xue-Ying</ForeName>
            <Initials>XY</Initials>
            <AffiliationInfo>
              <Affiliation>Shanghai Stomatology Hospital, Fudan University, Shanghai, 200001, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guan</LastName>
            <ForeName>Wei-Qun</ForeName>
            <Initials>WQ</Initials>
            <Identifier Source="ORCID">0000-0001-9270-9751</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Stomatology, Union Hospital, Fujian Medical University, Fuzhou, 350001, China. weiqunguandr_12@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>01</Month>
          <Day>22</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Inflammation</MedlineTA>
        <NlmUniqueID>7600105</NlmUniqueID>
        <ISSNLinking>0360-3997</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D064094">Interleukin-27</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007378">Interleukins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C464565">MYDGF protein, human</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D002294" MajorTopicYN="Y">Carcinoma, Squamous Cell</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006258" MajorTopicYN="Y">Head and Neck Neoplasms</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D064094" MajorTopicYN="Y">Interleukin-27</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007378" MajorTopicYN="N">Interleukins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007972" MajorTopicYN="N">Leukoplakia, Oral</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017676" MajorTopicYN="Y">Lichen Planus, Oral</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009062" MajorTopicYN="Y">Mouth Neoplasms</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077195" MajorTopicYN="N">Squamous Cell Carcinoma of Head and Neck</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">IL-27</Keyword>
        <Keyword MajorTopicYN="N">OLK</Keyword>
        <Keyword MajorTopicYN="N">OLP</Keyword>
        <Keyword MajorTopicYN="N">OSCC</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>22</Day>
          <Hour>5</Hour>
          <Minute>45</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35064378</ArticleId>
        <ArticleId IdType="doi">10.1007/s10753-021-01599-5</ArticleId>
        <ArticleId IdType="pii">10.1007/s10753-021-01599-5</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Fabbi, M., G. Carbotti, and S. Ferrini. 2017. Dual roles of IL-27 in cancer biology and immunotherapy. Mediators of Inflammation 2017: 3958069.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2017/3958069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lai, X., H. Wang, J. Cao, et al. 2016. Circulating IL-27 is elevated in rheumatoid arthritis patients. Molecules 21 (11): 1565.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/molecules21111565</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andrews, C., M.H. McLean, and S.K. Durum. 2016. Interleukin-27 as a novel therapy for inflammatory bowel disease: A critical review of the literature. Inflammatory Bowel Diseases 22 (9): 2255–2264.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MIB.0000000000000818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu, D., X. Zhou, L. Yao, C. Liu, F. Jin, and Y. Wu. 2014. Clinical implications of the interleukin 27 serum level in breast cancer. Journal of Investigative Medicine 62 (3): 627–631.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2310/JIM.0000000000000046</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garg, A., R. Trout, and S.A. Spector. 2017. Human immunodeficiency virus type-1 myeloid derived suppressor cells inhibit cytomegalovirus inflammation through interleukin-27 and B7–H4. Science and Reports 7: 44485.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/srep44485</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang, Z., J. Zak, I. Pratumchai, et al. 2019. IL-27 promotes the expansion of self-renewing CD8+ T cells in persistent viral infection. Journal of Experimental Medicine 216 (8): 1791–1808.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20190173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li, M.S., Z. Liu, J.Q. Liu, X. Zhu, Z. Liu, and X.F. Bai. 2015. The Yin and Yang aspects of IL-27 in induction of cancer-specific T-cell responses and immunotherapy. Immunotherapy 7 (2): 191–200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2217/imt.14.95</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han, Y., T. Su, L. Lin, et al. 2016. Clinical study on cervical lymph nodes metastasis of oral squamous cell carcinoma. Journal of Oral Science Research 32(02):154–157 (Article in China). https://kns.cnki.net/kcms/detail/detail.aspx?dbcode=CJFD&amp;dbname=CJFDLAST2016&amp;filename=KQYZ201602016&amp;v=ixgP%25mmd2Fpg844H6u%25mmd2FrQ%25mmd2Bur0zDT9df0D%25mmd2Foi2vHDXnhAokQSgdOhnGIxtGEaXSNyuYwTj</Citation>
        </Reference>
        <Reference>
          <Citation>Jemal, A., F. Bray, M.M. Center, J. Ferlay, E. Ward, D. Forman. 2011. Global cancer statistics [published correction appears in CA: a Cancer Journal for Clinicians 2011 61 (2): 134]. CA: a Cancer Journal for Clinicians 61 (2): 69–90.</Citation>
        </Reference>
        <Reference>
          <Citation>Cheng, Y.S., A. Gould, Z. Kurago, J. Fantasia, and S. Muller. 2016. Diagnosis of oral lichen planus: A position paper of the American Academy of Oral and Maxillofacial Pathology. Oral Surgery, Oral Medicine, Oral Pathology, and Oral Radiology 122 (3): 332–354.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.oooo.2016.05.004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>González-Moles, M.Á., P. Ramos-García, and S. Warnakulasuriya. 2020. An appraisal of highest quality studies reporting malignant transformation of oral lichen planus based on a systematic review. Oral Diseases. https://doi.org/10.1111/odi.13741 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/odi.13741</ArticleId>
            <ArticleId IdType="pubmed">33274561</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dong, Y., Y. Chen, Y. Tao, et al. 2019. Malignant transformation of oral leukoplakia treated with carbon dioxide laser: A meta-analysis. Lasers in Medical Science 34 (1): 209–221.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10103-018-2674-7</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharma, R., P. Narang, A.K. Sharma, et al. 2014. Prevalence of leukoplakia in patients visiting dental college in rural area of Jaipur, Rajasthan. Indian Journal of Public Health Research &amp; Development. 5 (3): 292–295.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5958/0976-5506.2014.00321.0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burgdorf, W.H., and G. Plewig. 2014. Who described civatte bodies? Journal of Cutaneous Pathology 41 (4): 340–346.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cup.12294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van der Waal, I. 2015. Oral leukoplakia, the ongoing discussion on definition and terminology. Medicina Oral, Patología Oral y Cirugía Bucal 20 (6): e685–e692.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4317/medoral.21007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang, H., J. Mao, L. Gao, J. Liu, and T. Wu. 2013. Effect of antisense TIMP-1 cDNA on the expression of TIMP-1 and MMP-2 in lung tissue with pulmonary fibrosis induced by bleomycin. Molecular Medicine Reports 7 (1): 149–153.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/mmr.2012.1140</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmidt-Westhausen, A.M. 2020. Oral lichen planus and lichenoid lesions: What’s new? Quintessence International 51 (2): 156–161.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31942576</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Piccinni, M.P., L. Lombardelli, F. Logiodice, et al. 2014. Potential pathogenetic role of Th17, Th0, and Th2 cells in erosive and reticular oral lichen planus. Oral Diseases 20 (2): 212–218.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/odi.12094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mashhadiabbas, F., and M. Fayazi-Boroujeni. 2017. Correlation of vascularization and inflammation with severity of oral leukoplakia. Iranian Journal of Pathology 12 (3): 225–230.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.30699/ijp.2017.25044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coppock, G.M., L.R. Aronson, J. Park, J.H. DeLong, E. Radaelli, K. Suszták, C.A. Hunter, et al. 2020. Loss of IL-27Rα results in enhanced tubulointerstitial fibrosis associated with elevated Th17 responses. The Journal of Immunology 205 (2): 377–386.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1901463</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Santana, P.T., J. Martel, H.C. Lai, J.L. Perfettini, J.M. Kanellopoulos, J.D. Young, R. Coutinho-Silva, and D.M. Ojcius. 2016. Is the inflammasome relevant for epithelial cell function? Microbes and Infection 18 (2): 93–101.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.micinf.2015.10.007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang, B., F. Xie, C.L. Dong, et al. 2017. The cross-talk between cervical carcinoma cells and vascular endothelial cells mediated by IL-27 restrains angiogenesis. American Journal of Reproductive Immunology 78 (4). https://doi.org/10.1111/aji.12706 .</Citation>
        </Reference>
        <Reference>
          <Citation>Xia, H., Z.J. Ye, Q. Zhou, et al. 2014. IL-27 and IL-27-producing CD4+ T cells in human tuberculous pleural effusion. Tuberculosis (Edinburgh, Scotland) 94 (6): 579–588.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tube.2014.07.003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Aquino, M.T., P. Kapil, D.R. Hinton, et al. 2014. IL-27 limits central nervous system viral clearance by promoting IL-10 and enhances demyelination. The Journal of Immunology 193 (1): 285–294.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1400058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nguyen, Q.T., E. Jang, H.T. Le, et al. 2019. IL-27 targets Foxp3+ Tregs to mediate anti-inflammatory functions during experimental allergic airway inflammation [published online ahead of print, 2019 Jan 24]. JCI Insight 4 (2): e123216.</Citation>
        </Reference>
        <Reference>
          <Citation>Pekiner, F.N., G.Y. Demirel, M.O. Borahan, and S. Ozbayrak. 2012. Cytokine profiles in serum of patients with oral lichen planus. Cytokine 60 (3): 701–706.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cyto.2012.08.007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tao, X.A., J. Xia, X.B. Chen, et al. 2010. FOXP3 T regulatory cells in lesions of oral lichen planus correlated with disease activity. Oral Diseases 16 (1): 76–82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1601-0825.2009.01608.x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun, Y., N. Liu, X. Guan, H. Wu, Z. Sun, and H. Zeng. 2016. Immunosuppression induced by chronic inflammation and the progression to oral squamous cell carcinoma. Mediators of Inflammation 2016: 5715719.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28053372</ArticleId>
            <ArticleId IdType="pmc">5178366</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cui, B., S. Lu, L. Lai, et al. 2017. Protective function of interleukin 27 in colitis-associated cancer via suppression of inflammatory cytokines in intestinal epithelial cells. Oncoimmunology. 6 (2): e1268309.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/2162402X.2016.1268309</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang, T., Y. Chen, H. Nie, Y. Huang, Y. Zhao, and J. Yang. 2019. IL-27 inhibits non-small-cell lung cancer cell metastasis by miR-935 in vitro. Oncotargets and Therapy 12: 1447–1454.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/OTT.S173207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ge, H., N. Yin, T.L. Han, et al. 2019. Interleukin-27 inhibits trophoblast cell invasion and migration by affecting the epithelial-mesenchymal transition in preeclampsia. Reproductive Sciences 26 (7): 928–938.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1933719118799206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Di Carlo, E., C. Sorrentino, A. Zorzoli, et al. 2014. The antitumor potential of Interleukin-27 in prostate cancer. Oncotarget 5 (21): 10332–10341.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.1425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goertzen, C., H. Mahdi, C. Laliberte, et al. 2018. Oral inflammation promotes oral squamous cell carcinoma invasion. Oncotarget 9 (49): 29047–29063.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.25540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qian, Y., W. Yao, T. Yang, et al. 2017. aPKC-ι/P-Sp1/snail signaling induces epithelial-mesenchymal transition and immunosuppression in cholangiocarcinoma. Hepatology 66 (4): 1165–1182.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.29296</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park, Y.J., H. Ryu, G. Choi, et al. 2019. IL-27 confers a protumorigenic activity of regulatory T cells via CD39. Proceeding of the National Academy of Sciences U S A. 116 (8): 3106–3111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1810254116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Babadi, A.S., A. Kiani, E. Mortaz, et al. 2019. Serum interleukin-27 level in different clinical stages of lung cancer. Open Access Macedonian Journal of Medical Sciences 7 (1): 45–49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3889/oamjms.2019.018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kopiński, P., T. Wandtke, A. Dyczek, et al. 2018. Increased levels of interleukin 27 in patients with early clinical stages of non-small cell lung cancer. Polish Archives of Internal Medicine 128 (2): 105–114.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29187726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bisevac, J.P., I. Stanojevic, Z. Mijuskovic, T. Banovic, M. Djukic, and D. Vojvodic. 2016. High interleukin 27 production is associated with early clinical stage and localized disease in patients with melanoma. Journal of Medical Biochemistry 35 (4): 443–450.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1515/jomb-2016-0018</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
